A RetroSearch Logo

Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Search Query:

Showing content from https://pubmed.ncbi.nlm.nih.gov/33621333/ below:

Significant Declines in Juvenile-onset Recurrent Respiratory Papillomatosis Following Human Papillomavirus (HPV) Vaccine Introduction in the United States

. 2021 Sep 7;73(5):885-890. doi: 10.1093/cid/ciab171. Significant Declines in Juvenile-onset Recurrent Respiratory Papillomatosis Following Human Papillomavirus (HPV) Vaccine Introduction in the United States

Affiliations

Affiliations

Item in Clipboard

Significant Declines in Juvenile-onset Recurrent Respiratory Papillomatosis Following Human Papillomavirus (HPV) Vaccine Introduction in the United States

Elissa Meites et al. Clin Infect Dis. 2021.

. 2021 Sep 7;73(5):885-890. doi: 10.1093/cid/ciab171. Affiliations

Item in Clipboard

Abstract

Background: Juvenile-onset recurrent respiratory papillomatosis (JORRP) is a rare and serious disease caused by human papillomavirus (HPV) presumably acquired during vaginal delivery. HPV vaccination of females through age 26 years, recommended in the United States since 2006, can prevent HPV transmission. We assessed trends in JORRP cases before and after HPV vaccine introduction in the United States.

Methods: Case-patients were identified from 26 pediatric otolaryngology centers in 23 U.S. states. Demographics and clinical history were abstracted from medical records. Case-patients were grouped by year of birth, and birth-cohort incidences were calculated using number of births from either national or state-level natality data from the 23 states. We calculated incidence rate ratios (IRR) and 95% confidence intervals (CI) in 2-year intervals.

Results: We identified 576 U.S. JORRP case-patients born in 2004-2013. Median age at diagnosis was 3.4 years (interquartile range: 1.9, 5.5). Number of identified JORRP case-patients declined from a baseline of 165 born in 2004-2005 to 36 born in 2012-2013. Incidence of JORRP per 100 000 births using national data declined from 2.0 cases in 2004-2005 to 0.5 cases in 2012-2013 (IRR = 0.2, 95% CI = .1-.4); incidence using state-level data declined from 2.9 cases in 2004-2005 to 0.7 cases in 2012-2013 (IRR = 0.2, 95% CI = .1-.4).

Conclusions: Over a decade, numbers of JORRP case-patients and incidences declined significantly. Incidences calculated using national denominator data are likely underestimates; those calculated using state-level denominator data could be overestimates. These declines are most likely due to HPV vaccination. Increasing vaccination uptake could lead to elimination of this HPV-related disease.

Keywords: child health; human papillomavirus (HPV); papillomavirus infections; papillomavirus vaccines; recurrent respiratory papillomatosis.

Published by Oxford University Press for the Infectious Diseases Society of America 2021.

PubMed Disclaimer

Figures

Figure 1.

Study periods and birth years…

Figure 1.

Study periods and birth years of US children with juvenile-onset recurrent respiratory papillomatosis…

Figure 1.

Study periods and birth years of US children with juvenile-onset recurrent respiratory papillomatosis (JORRP) included in analytic period. Abbreviation: HPV, human papillomavirus. *Median age at JORRP diagnosis in our overall dataset (age 4 years) was used to determine birth years from enrollment data, based on the assumption that birth year was when each JORRP case-patient acquired their causative HPV infection. The analytic period included birth years from 2004 throungh 2013, beginning 4 years before the earliest consistent date of data retrieval in 2008, and ending 4 years before the most recent completed data collection in 2017.

Figure 2.

States with at least 1…

Figure 2.

States with at least 1 medical center participating in the juvenile-onset recurrent respiratory…

Figure 2.

States with at least 1 medical center participating in the juvenile-onset recurrent respiratory papillomatosis (JORRP) monitoring study.

Figure 3.

Juvenile-onset recurrent respiratory papillomatosis (JORRP)…

Figure 3.

Juvenile-onset recurrent respiratory papillomatosis (JORRP) case-patients by birth year and incidence based on…

Figure 3.

Juvenile-onset recurrent respiratory papillomatosis (JORRP) case-patients by birth year and incidence based on US national or state-level denominator data.

Similar articles Cited by References
    1. Derkay CS, Bluher AE. Update on recurrent respiratory papillomatosis. Otolaryngol Clin North Am 2019; 52:669–79. - PubMed
    1. Lawlor C, Balakrishnan K, Bottero S, et al.International Pediatric Otolaryngology Group (IPOG): juvenile-onset recurrent respiratory papillomatosis consensus recommendations. Int J Pediatr Otorhinolaryngol 2020; 128:109697. - PubMed
    1. Buchinsky FJ, Valentino WL, Ruszkay N, et al.Age at diagnosis, but not HPV type, is strongly associated with clinical course in recurrent respiratory papillomatosis. PLoS One 2019; 14:e0216697. - PMC - PubMed
    1. Preciado D, Tunkel D, Zalzal G. Pediatric otolaryngology in the United States: demographics, workforce perceptions, and current practices. Arch Otolaryngol Head Neck Surg 2009; 135:8–13. - PubMed
    1. Armstrong LR, Derkay CS, Reeves WC. Initial results from the national registry for juvenile-onset recurrent respiratory papillomatosis. RRP Task Force. Arch Otolaryngol Head Neck Surg 1999; 125:743–8. - PubMed

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3